Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 5/20 | 0.45 |
| ▸ | MMP12 | P39900 | 5/20 | 0.45 |
| ▸ | MMP13 | P45452 | 5/20 | 0.45 |
| ▸ | MMP14 | P50281 | 5/20 | 0.45 |
| ▸ | MMP8 | P22894 | 4/20 | 0.45 |
| ▸ | MMP16 | P51512 | 4/20 | 0.45 |
| ▸ | MMP9 | P14780 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP3 | P08254 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928696 | 0.85 | CA12 (0.43) | MMP2MMP12MMP13MMP14MMP8 | |
| SCHEMBL6479739 | 0.82 | MMP2 (0.55) | MMP2MMP12MMP13MMP14MMP8 | |
| SCHEMBL29131708 | 0.76 | TDP1 (0.61) | MEN1KMT2AALDH1A1KDM4ETDP1 | |
| SCHEMBL3916747 | 0.75 | KDM4E (0.43) | MMP2MMP12MMP13MMP14MMP8 | |
| SCHEMBL3919955 | 0.72 | L3MBTL1 (0.55) | L3MBTL1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL6478231 | 0.71 | MMP2 (0.52) | MMP2MMP12MMP13MMP14MMP8 | |
| SCHEMBL12936006 | 0.70 | TDP1 (0.58) | MEN1KMT2AALDH1A1KDM4ETDP1 | |
| SCHEMBL218722 | 0.70 | AKR1B1 (0.61) | MEN1KMT2AALDH1A1KDM4ETDP1 | |
| SCHEMBL9394407 | 0.68 | ALDH1A1 (0.56) | L3MBTL1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL6069328 | 0.68 | MMP2 (0.58) | MMP2MMP12MMP13MMP14MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534787-B2 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-19 | — | — | US | disclosed |
| US-20090099159-A1 | Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-7393843-B2 | Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-20080139541-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BORNEMANN KLAUS | 2008-06-12 | — | — | US | disclosed |
| US-7375220-B2 | Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| EP-1750719-A2 | TREATMENT OF DISEASES ASSOCIATED WITH ALTERED LEVEL OF AMYLOID BETA PEPTIDES | Boehringer Ingelheim International GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| US-20060040928-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2006-02-23 | — | — | US | disclosed |
| US-20050277635-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
| WO-2005110422-A2 | TREATMENT OF DISEASES ASSOCIATED WITH ALTERED LEVEL OF AMYLOID BETA PEPTIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040928-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | APP, BACE1, PSEN1 | L3MBTL1 311/4885MMP2 1983/4885MMP12 2319/4885 |
| US-20090099159-A1 | Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds | APP, BACE1, PSEN1 | L3MBTL1 311/4885MMP2 1983/4885MMP12 2319/4885 |
| US-20050277635-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | APP, BACE1, PSEN1 | L3MBTL1 311/4885MMP2 1983/4885MMP12 2319/4885 |
| US-20080139541-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | APP, BACE1, PSEN1 | L3MBTL1 320/4885MMP2 1980/4885MMP12 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.